<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir, a guanine analogue, effectively inhibits the RNA‐dependent polymerase of RNA viruses. This anti‐viral effect has efficacy on influenza (approved use), Ebola, yellow fever, chikungunya, norovirus and enterovirus. Activity against COVID‐19 has been reported.
 <xref rid="apt15779-bib-0112" ref-type="ref">
  <sup>112</sup>
 </xref> It is currently being tested in Japan and has no significant drug interactions. In a recent study it has been reported to improve clinical recovery rates at day 7 when compared to arbidol, a flu medication (71% vs. 56%) but there was no difference in auxiliary oxygen or non‐invasive ventilation requirements.
 <xref rid="apt15779-bib-0113" ref-type="ref">
  <sup>113</sup>
 </xref>
</p>
